Â鶹ӳ»­

MD Anderson was awarded $22.3 million from the Cancer Prevention and Research Institute of Texas (CPRIT), accounting for 30% of the $73.5 million in awards CPRIT announced in February. The awards included $16.3 million for individual investigator research including awards for cancer in children and adolescents, computational biology, clinical translation, and prevention and early detection. MD Anderson also received $2 million for recruitment and $4 million for a colorectal cancer prevention coalition award.

¡°As our team of experts at MD Anderson works to advance understanding and treatment of cancer, we remain grateful to the Cancer Prevention and Research Institute of Texas for its support,¡± said Peter WT Pisters, M.D., president of MD Anderson. ¡°These critical funds enhance our ability to find new therapeutic and preventive approaches for our patients and help further our mission to end cancer in Texas and beyond.¡±

CPRIT awards to MD Anderson included:

Individual Investigator Awards

• Hippo signaling in non-alcoholic fatty liver disease (NAFLD) and it progression to hepatocellular carcinoma () ¨C $821,669
• Inhibiting Oxidative Phosphorylation: A Novel Strategy in Leukemia (Marina Konopleva, M.D., Ph. D., Leukemia) ¨C $900,000
• PTEN Promotes Diabetic breast cancer metastasis () ¨C $900,000
• A somatic mutant p53 mouse model of metastatic triple negative breast cancer () ¨C $900,000
• Targeting the prion protein Doppel in brain tumor angiogenesis () ¨C $900,000
• Mucosal vaccine formulations for targeted therapy of HPV cancers () ¨C $883,146
• Functional analyses of linkage-specific ubiquitination in the DNA damage response () ¨C $900,000
• Targeting neutrophil elastase as a novel therapy for metastatic breast cancer () ¨C $900,000

Individual Investigator Awards for Cancer in Children and Adolescents

• Molecular mechanisms of anthracycline response in cardiomyocytes and link to genetic susceptibility to cardiotoxicity in long-term childhood cancer survivors () ¨C $1,194,520
• Compound heterozygous mutations in pediatric cancer predisposition () ¨C $556,763

Individual Investigator Awards for Computational Biology

Characterizing cancer genome instability and translational impact using new sequencing technologies () ¨C $898,997

Individual Investigator Awards for Clinical Translation

• EXTernal beam radiation to Eliminate Nominal metastatic Disease (EXTEND): A randomized phase II basket trial to assess local control of oligometastatic disease () ¨C $2,394,412
• Clinical trials of C188-9, an oral inhibitor of signal transducer and activator of transcription (STAT) 3, in patients with hepatocellular carcinoma (HCC) () ¨C $2,399,905

Individual Investigator Awards for Prevention and Early Detection

• Blood-based biomarkers for the early detection of pancreatic cancer () ¨C $900,000
• Circulating Exosomes as Biomarkers for Lung Cancer Early Detection () ¨C $799,085

Colorectal Cancer Prevention Coalition Awards

Alliance for Colorectal Cancer Testing 2.0 (ACT 2.0) (Lewis Foxhall, M.D., Health Policy, Clinical Operations) ¨C $4,034,507

Recruitment of First-Time, Tenure ¨C Track Faculty Member Awards

Recruitment of a top prostate cancer expert ¨C $2 million.